Incyte's Ruxolitinib Works in Patients With Eczema
The biotech company just reported data from a pair of successful late-stage clinical trials.
Incyte
INCY
INCY
$80.89
-$1.88
-2.3%
Price as of February 21, 2020, 4:30 p.m. EST
View Interactive INCY Charts
The Company is a drug discovery and development company focused on developing proprietary small molecule drugs to treat serious unmet medical needs.
Interactive Chart
News & Analysis: Incyte
The Fool has written over 200 articles on Incyte.
Better Buy: Vertex Pharmaceuticals vs. Incyte
Big drug developers reinvest revenues from cash-cow products to fuel the pipeline for the future.
Incyte Corp (INCY) Q4 2019 Earnings Call Transcript
INCY earnings call for the period ending December 31, 2019.
How Incyte Beat Wall Street Estimates in Q4
The biotech posted strong sales growth for all three of its approved drugs.
Incyte's Fourth-Quarter Report Signals Better Times Ahead
Though the pharmaceutical company reported a big clinical trial failure last month, there are other reasons for optimism.
Eli Lilly and Incyte Record Another Positive Clinical Trial for Olumiant Works in Eczema
The drug moves closer to an expanded approval for the skin disorder.
Potential Lung Cancer Drug from Incyte and Novartis to Get a Priority Review from FDA
The Food and Drug Administration will expedite its review of capmatinib.
Stocks to Watch in February
These three stocks have major events coming up this month -- and it's not just the release of earnings that investors will be watching.
Here's Why Incyte Stock Tumbled 16.3% in January
A failed study disappointed investors, but the company's pipeline should withstand the blow.
Incyte's Eczema Drug Ruxolitinib Works in a Late-Stage Clinical Trial
But the biotech won't release details about how well it works until later.
